Nektar Therapeutics

Nektar Therapeutics

Yahoo Finance • 6 days ago

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here. In Q3 2026, Cedar Grove Capital Management's Multi-Strategy Composite returned -1... Full story

Yahoo Finance • 12 days ago

This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?

Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug. Continue Reading... Full story

Yahoo Finance • 18 days ago

Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading

Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 18 days ago

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 18 days ago

Nektar Therapeutics stock rises on $90M jury verdict vs Lilly

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) shares rose 3.6% in premarket trading Friday following a jury verdict awarding the company $90 million in damages in a contract dispute with Eli Lilly and Company (NYSE:LLY). Still guessi... Full story

Yahoo Finance • 18 days ago

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 21 days ago

Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg

[Digital Justice and Legal Tech Concept with Scales of Justice Icon and Circuit Network] jittawit.21/iStock via Getty Images Nektar Therapeutics (NKTR [https://seekingalpha.com/symbol/NKTR]) quickly sank 11% as a jury deliberated in its p... Full story

Yahoo Finance • 2 months ago

Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test

On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 tr... Full story

Yahoo Finance • 2 months ago

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleuki... Full story

Yahoo Finance • 2 months ago

Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more

[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consu... Full story

Yahoo Finance • 4 months ago

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Quick Read AbbVie (ABBV) proved big pharma will pay up for late-stage immunology with the Apogee deal, reigniting M&A speculation across the biotech sector. Syndax (SNDX) earns the top takeover ranking with two FDA-approved drugs, 224% re... Full story

Yahoo Finance • 4 months ago

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock

Nektar Therapeutics (NASDAQ:NKTR) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Wedbush analyst Martin Fan decreased the price target on Nektar Therapeutics (NASDAQ:NKTR) from $95 to $80 wh... Full story

Yahoo Finance • 5 months ago

Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off

[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell... Full story

Yahoo Finance • 5 months ago

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch

On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of Nektar Therapeutics(NASDAQ:NKTR), an estimated $10.27 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • 5 months ago

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics(NASDAQ:NKTR). The estimated value of the trade was... Full story

Yahoo Finance • 5 months ago

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, May 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or othe... Full story

Yahoo Finance • 5 months ago

NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & Korsinsky

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Nektar Therapeutics (NASDAQ: NKTR) promised investors a rigorously controlled Phase 2b clinical trial. The results told a different story. Find out if you can recover your investment losses or c... Full story

Yahoo Finance • 5 months ago

NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options If you purchased or acquired Nektar securities between February 26, 2... Full story

Yahoo Finance • 5 months ago

NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR

NEW YORK, May 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclus... Full story

Yahoo Finance • 6 months ago

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeu... Full story